Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Cyteir Therapeutics, Inc.CYT-3.270.000.870.52-23.80%-37.88%0.00$2.65$4.84-$3.01

Detail of Cyteir Therapeutics, Inc.

 
CEO
Dr. Markus F. Renschler M.D.
Employees
40
Industry
Biotechnology
Sector
Healthcare
Market cap
$108M

Company details

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Cyteir Therapeutics, Inc.
CYT • XNGS • US
$3 .01
+0.22 (7.89%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.92
Margin profit
0.00%
52 week low
$2.78
52 week high
$3.15
50-day simple moving average
$0.00
200-day simple moving average
$3.02
Percent held by insiders
11.95%
Percent held by institutions
73.65%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
CYT +7.89%
eps change
CYT 0.00%